← All trials
NCT06416865
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2022
- Primary completion
- Dec 12, 2022
- Completion date
- Aug 31, 2024
- First posted
- May 16, 2024
- Last posted
- May 22, 2024
- Enrollment
- 190
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aju PharmLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.